Actions of butyrophenones and other antipsychotic agents at NMDA receptors: Relationship with clinical effects and structural considerations

Neurochemistry International

Volumn 34, Issue 2, 1999, Pages 167-175

  Shim, S S ^a   Grant, E R ^a   Singh, S ^a   Gallagher, M J ^a   Lynch, D R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BUTACLAMOL; BUTYROPHENONE DERIVATIVE; CLOZAPINE; DIZOCILPINE; FLUPHENAZINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PIMOZIDE; RISPERIDONE; SPIPERONE; SULPIRIDE; TRIFLUOPERAZINE; TRIFLUPERIDOL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BUTYROPHENONES; DIZOCILPINE MALEATE; IODINE RADIOISOTOPES; RADIOLIGAND ASSAY; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; SPERMIDINE;

EID: 0032976752     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(98)00085-0     Document Type: Article

References (48)

1. Arts, M., Bemelmans, F., Cools, A., 1998. Activation of N-methyl-D-aspartate receptors in the feline retrorubral nucleus elicits orofacial dyskinesia. European Journal of Pharmacology 349, 23-31.
2. Banerjee, S.P., Zuck, L.G., Yablonsky-Alter, E., Lidsky, T.I., 1995. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Neuroreport 6, 2500-2504.
3. Brimecombe, J.C., Gallagher, M.J., Lynch, D.R., Aizenman, E., 1998. An NR2B point mutation affecting haloperidol and CP101,606 sensitivity of single recombinant N-methyl-D-aspartate receptors. Journal of Pharmacology and Experimental Therapeutics 286, 627-634.
4. Butler, T.W., Blake, J.F., Bordner, J., Butler, P., Chenard, B.L., Collins, M.A., DeCosta, D., Ducat, M.J., Eisenhard, M.E., Menniti, F.S., Pagnozzi, M.J., Sands, S.B., Segelstein, B.E., Volberg, W., White, W.F., Zhao, D., 1998. (3R,4 S)-3- [4- (4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1 S,2 S)1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)1-propanol. Journal of Medicinal Chemistry 41, 1172-1184.
5. Chang, W-H., Jann, M.W., Chiang, T.S., Lin, H.N., Hu, W.H., Chien, C.P., 1996. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population. Neuropsychobiology 33, 12-16.
6. Chazot, P.L., Coleman, S.K., Cik, M., Stephenson, F., 1994. Molecular characterization of N-methyl-D-aspartate receptors expressed in mammalian cells yields evidence for the coexistence of three subunit types within a discrete receptor molecule. Journal of Biological Chemistry 269, 24403-24409.
7. Chen, C., Okayama, H., 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Molecular and Cellular Biology 7, 2745-2752.
8. Chenard, B.L., Bordner, J., Butler, T.W., Chambers, L.K., Collins, M.A., De Costa, D.L., Ducat, M.F., Dumont, M.L., Fox, C.B., Mena, E.E., 1995. (1 S,2 S)-1- (4-hydroxyphenyl)-2- (4-hydroxy-4-phenylpiperidino)-1-propanol: A potent new neuroprotectant which blocks N-methyl-D-aspartate responses. Journal of Medicinal Chemistry 38, 3138-3145.
9. Choi, D.W., Rothman, S.M., 1990. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annual Review of Neuroscience 13, 171-182.
10. Constantine-Paton, M., Cline, H.T., 1998. LTP and activity-dependent synaptogenesis: the more alike they are, the more different they become. Current Opinion in Neurobiology 8, 139-148.
11. Coughenour, L.L., Cordon, J., 1997. Characterization of haloperidol and trifluperidol as subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonists using [3H]TCP and [3H]ifenprodil binding in rat brain membranes. Journal of Pharmacology and Experimental Therapeutics 280, 584-592.
12. Fischer, G., Mutel, V., Trube, G., Malherbe, P., Kew, J.N., Mohacsi, E., Heitz, M.P., Kemp, J.A., 1997. Ro 25-698 1, a highly potent and selective blocker of N-methyl-Daspartate receptors containing the NR2B subunit: Characterization in vitro. Journal of Pharmacology and Experimental Therapeutics 283, 1285-1292.
13. Gallagher, M.J., Huang, H., Lynch, D.R., 1998. Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions. Journal of Neurochemistry 70, 2120-2128.
14. Gallagher, M.J., Huang, H., Grant, E.R., Lynch, D.R., 1997. The NR2B specific interactions of polyamines and protons with the N-methyl-D-aspartate receptor. Journal of Biological Chemistry 272, 24971-24979.
15. Gallagher, M.J., Huang, H., Pritchett, D.B., Lynch, D., 1996. Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. Journal of Biological Chemistry 271, 9603-9611.
16. Grimm, J.W., Kruzich, P.J., See, R.E., 1998. Emergence of oral and locomotor activity in chronic haloperidol-treated rats following cortical N-methyl-D-aspartate stimulation. Pharmacology Biochemistry and Behavior 60, 167-173.
17. Harris, P.Q., Brown, S.J., Friedman, M.J., Bacopoulos, N.G., 1984. Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics. Biological Psychiatry 19, 849-860.
18. Ikeda, K., Nagasawa, M., Mori, H., Araki, K., Sakimura, K., Watanabe, M., Inoue, Y., Mishina, M., 1992. Cloning and expression of the ε 4 subunit of the NMDA receptor channel. FEBS Letters 313, 34-38.
19. Ilyin, V.I., Whittemore, E.R., Guastella, J., Weber, E., Woodward, R.M., 1996. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Molecular Pharmacology 50, 1541-1550.
20. Ishii, T., Moriyoshi, K., Sugihara, H., Sakurada, K., Kadotani, H., Yokoi, M., Akazawa, C., Shigemoto, R., Mizuno, N., Masu, M., Nakanishi, S., 1993. Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. Journal of Biological Chemistry 268, 2836-2843.
21. Javitt, D.C., Zukin, R.S., 1991. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
22. Kloog, Y., Haring, R., Sokolovsky, M., 1988. Kinetic characterization of the phencyclidine-N-methyl-D-aspartate receptor interaction, evidence for a steric blockade of the channel. Biochemistry 27, 843-848.
23. Kosinski, C.M., Standaert, D.G., Counihan, T.J., Scherzer, C.R., Kerner, J.A., Daggett, L.P., Velicelebi, G., Penney, J.B., Young, A.B., Landwehrmeyer, G.B., 1998. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus. Journal of Comparative Neurology 390, 63-74.
24. Kutsuwada, T., Kashiwabuchi, N., Mori, H., Sakimura, K., Kushiya, E., Araki, K., Meguro, H., Masaki, H., Kumanishi, T., Arakawa, M., Mishina, M., 1992. Molecular diversity of the NMDA receptor channel. Nature 358, 34-36.
25. Lidsky, T.I., Yablonsky-Alter, E., Zuck, L.G., Banerjee, S.P., 1997. Antipsychotic drug effects on glutamatergic activity. Brain Research 764, 46-52.
26. Lovinger, D.M., 1995. Developmental decrease in ethanol inhibition of N-methyl-Daspartate receptors in rat neocortical neurons: Relation to the actions of ifenprodil. Journal of Pharmacology and Experimental Therapeutics 274, 164-172.
27. Luo, J-P., Hubbard, J.W., Midha, K.K., 1997. Sensitive method for the simultaneous measurement of fluphenazine decanoate in plasma by high performance liquid chromatography with coulometric detection. Journal of Chromatography 688, 303-308.
28. Luo, J., Wang, Y., Yasuda, R.P., Dunah, A.W., Wolfe, B.B., 1997. The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B). Molecular Pharmacology 51, 79-86.
29. Lynch, D.R., Anegawa, N.J., Verdoorn, T., Pritchett, D.B., 1994. N-methyl-Daspartate receptors: Different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents. Molecular Pharmacology 45, 540-545.
30. Lynch, D.R., Gallagher, M.J., 1996. Inhibition of N-methyl-D-aspartate receptors by haloperidol, developmental and pharmacological characterization in native and recombinant receptors. Journal of Pharmacology and Experimental Therapeutics 279, 154-161.
31. Lynch, D.R., Lawrence, J.J., Lenz, S., Anegawa, N.J., Dichter, M., Pritchett, D.B., 1995. Pharmacological characterization of heterodimeric NMDA receptors composed of NR1a and 2B subunits, differences with receptors formed from NR1a and 2A. Journal of Neurochemistry 64, 1462-1468.
32. Lynch, D.R., Grant, E.R., Singh, S., Gallagher, M.J., 1997. Antipsychotic action at NMDA receptors: Evidence from brain and heterologous expression systems. Society for Neuroscience Abstracts 27, 933.
33. Mannens, G., Meuldermans, W., Snoeck, E., Heykants, J., 1994. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology 114, 566-572.
34. Meguro, H., Mori, H., Araki, K., Kushiya, E., Kutsuwada, T., Yamazaki, M., Kumanishi, T., Arakawa, M., Sakimura, K., Mishina, M., 1992. Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 357, 70-74.
35. Miller, A.Y., Kleckner, N.W., 1997. Effects of Clozapine and chlorpromazine on NR1-NR2A and NR1-NR2B subtypes of the N-methyl-D-aspartate receptor. Society for Neuroscience Abstracts 27, 919.
36. Monaghan, D.T., Larsen, H., 1997. NR1 and NR2 subunit contributions to N-methyl-Daspartate receptor channel blocker pharmacology. Journal of Pharmacology and Experimental Therapeutics 280, 614-620.
37. Monteiro, L.M., 1985. Tardive dyskinesia controlled by anticholinergic agents. Clinical Neuropharmacology 8, 372-376.
38. Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomel, H., Burnashev, N., Sakmann, B., Seeburg, P.H., 1992. Heteromeric NMDA receptors, molecular and functional distinction of subtypes. Science 256, 1217-1221.
39. Moriyoshi, K., Masu, M., Ishii, T., Shigemoto, R., Mizuno, N., Nakanishi, S., 1991. Molecular cloning and characterization of the rat NMDA receptor. Nature 354, 31-37.
40. Perry, P.J., Miller, D.D., Arndt, S.V., Cadoret, R.J., 1991. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. American Journal of Psychiatry 148, 231-235.
41. Potkin, S.G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., Richmond, G., Carreon, D., Sitanggan, K., Gerber, B., 1994. Plasma clozapine concentrations predict clinical response in treatment resistant schizophrenia. Journal of Clinical Psychiatry 55, 133-136.
42. Van Kammen, D.P., Kelley, M.E., Yao, J.K., Gilbertson, M.W., Gurklis, J.A., Inosaka, T., Saito, H., Peters, J.L., Sato, M., 1996. Predicting haloperidol treatment response in chronic schizophrenia. Psychiatric Research 64, 47-58.
43. Verma, A., Kulkarni, S.K., 1992. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Psychopharmacology 109, 477-483.
44. Whittemore, E.R., Ilyin, V.I., Woodward, R.M., 1997. Antagonism of N-methyl-Daspartate receptors by σ site legends: Potency, subtype-selectivity and mechanisms of inhibition. Journal of Pharmacology and Experimental Therapeutics 282, 326-338.
45. Williams, K., Dichter, M.A., Molinoff, P.B., 1992. Up-regulation of N-methyl-Daspartate receptors on cultured cortical neurons after exposure to antagonists. Molecular Pharmacology 42, 147-151.
46. Yamakura, T., Sakimura, K., Mishina, M., Shimoji, K., 1998. Sensitivity of the N-methyl-D-aspartate receptor channel to butyrophenones is dependent on the ε2 subunit. Neuropharmacology 37, 709-717.
47. Zhong, J., Russell, S.L., Pritchett, D.B., Molinoff, P.B., Williams, K., 1994. Expression of mRNAs encoding subunits of the N-methyl-D-aspartate receptor in cultured cortical neurons. Molecular Pharmacology 45, 846-853.
48. Zhong, J., Carrozza, D.P., Williams, K., Pritchett, D.B., Molinoff, P.B., 1995. Expression of mRNAs encoding subunits of the NMDA receptor in developing rat brain. Journal of Neurochemistry 64, 531-539.